Radiation therapy for prostate cancer in the new S3 guideline. Part 2: Postoperative radiation therapy and brachytherapy;Strahlentherapie des Prostatakarzinoms in der Neuen S3-leitlinie Teil 2: Postoperative Strahlentherapie und Brachytherapie

Urologe - Ausgabe A

Volumn 49, Issue 2, 2010, Pages 216-220

  Martin, T ^a   Wenz, F ^b   Bohmer D ^c   Sedlmayer, F ^d   Hinkelbein, W ^c   Henkel, T O ^e   Miller, K ^c   Wiegel, T ^f  

^a KLINIKUM BREMEN MITTE   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Univ S   (Austria)

^e Campus Benjamin Franklin ^*  (Germany)

^f UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Hdr brachytherapy; Ldr brachytherapy; Postoperative radiation therapy; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE SEVERITY; HUMAN; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; REVIEW; RISK ASSESSMENT; S3 GUIDELINE; TREATMENT INDICATION;

ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; MALE; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77952639473     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-010-2242-7     Document Type: Review

References (35)

1. Blasko JC, Grimm PD, Sylsvester JE, Cavanagh W (2000) The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 57(3):273-278
2. Bolla M, Poppel H van, Collette L et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366(9485):572-578 (Pubitemid 41140332)
3. Bottke D, Reijke TM de, Barkowlak D, Wiegel T (2009) Salvage radiotherapy In patients with persisting/rising PSA after radical prostatectomy for prostate cancer. Eur J Cancer 45(Suppl 1):148-157
4. Catton C, Gospodarowicz M, Warde P et al (2001) Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 59(1):51-60 (Pubitemid 32261076)
5. Collette L, Poppel H van, Bolla M et al (2005) Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate postoperative irradiation? (EORTC trial 22911). Eur J Cancer 41(17):2662-2672 (Pubitemid 41607557)
6. Corner C, Rojas AM, Bryant L et al (2008) A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 72(2):441-446
7. Deger S, Boehmer D, Roigas J et al (2005) High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 47(4):441-448 (Pubitemid 40357885)
8. Demanes DJ, Rodriguez RR, Schour L et al (2005) High-dose-rate intensitymodulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurletherapy's 10-year results. Int J Radiat Oncol Biol Phys 61(5):1306-1316
9. Galalae RM, Martinez A, Mate T et al (2004) Longterm outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58(4):1048-1055 (Pubitemid 38314785)
10. Galalae RM, Martinez A, Nuernberg N et al (2006) Hypofractionated conformal HDR brachytherapy In hormone naive men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlenther Onkol 182(3):135-141
11. Ganswindt U, Stenzl A, Bamberg M, Belka C (2008) Adjuvant radiotherapy for patients with locally advanced prostate cancer-a new standard? Eur Urol 54(3):528-542
12. Garg MK, Tekyi-Mensah S, Bolton S et al (1998) Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 51 (6):998-1002 (Pubitemid 28240861)
13. Hoskin PJ, Motohashi K, Bownes P et al (2007) High dose rate brachytherapy In combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 84(2):114-120 (Pubitemid 47284526)
14. Khaksar SJ, Langley SE, Lovell D, Laing RW (2006) Interstitial low dose rate brachytherapy for prostate cancer-a focus on intermediate- and high-risk disease. Clin Oncol (R Coll Radiol) 18(7):513-518 (Pubitemid 44123549)
15. Kovacs G, Potter R, Loch T et al (2005) GEC/ESTROEAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol 74(2):137-148 (Pubitemid 40331870)
16. Loeb S, Roehl KA, Viprakasit DP, Catalona WJ (2008) Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. Eur Urol 54(1):88-94
17. Martin T, Baltas D, Kurek R et al (2004) 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 180(4):225-232 (Pubitemid 38461547)
18. Martinez AA, Pataki I, Edmundson G et al (2001) Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 49(1):61-69 (Pubitemid 32041277)
19. Merrick GS, Butler WM, Galbreath RW et al (2003) Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer? BJU Int 91(1):23-29
20. Morgan SC, Waldron TS, Eapen L et al (2008) Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol 88(1):1-9
21. Nilsson S, Norlen BJ, Widmark A (2004) A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 43(4)316-381 (Pubitemid 38887858)
22. Pasquier D, Ballereau C (2008) Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review, Int J Radiat Oncol Biol Phys 72(4):972-979
23. Potters L, TorreT, Ashley R, Leibel S (2000) Examining the role of neoadjuvant androgen deprivation In patients undergoing prostate brachytherapy. J Clin Oncol 18(6):1187-1192 (Pubitemid 30159835)
24. Sathya JR, Davis IR, Julian JA et al (2005) Randomized trial comparing Iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone In node-negative locally advanced cancer of the prostate. J Clin Oncol 23(6):1192-1199 (Pubitemid 46202276)
25. Sautter-Bihl ML, Sedlmayer F, Wiegel T (2009) Postoperative radiotherapy for advanced prostate cancer:improved local control translates into increased survival. Strahlenther Onkol 185(8):485-487
26. Sharkey J, Cantor A, Solc Z et al (2005) 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12year experience from a single group practice. Brachytherapy 4(1):34-44 (Pubitemid 40292828)
27. Stephenson AJ, Scardino PT, Katton MW et al (2007) Predicting the outcome of slavage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035-12034
28. Sylvester JE, Blasko JC, Grimm PD et al (2003) Tenyear biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 57(4):944-952 (Pubitemid 37324111)
29. Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956-962
30. Thompson IM Jr, Tangen CM, Paradelo J et al (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296(19):2329-2335 (Pubitemid 44749360)
31. Track BJ, Han M, Freedland SJ et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299(23):2760-2769 (Pubitemid 351846851)
32. Van der Kwast TH, Bolla M, Van Poppel H et al (2007) EORTC 22911. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25(27):4178-4186 (Pubitemid 47548556)
33. Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27(18):2924-2930
34. Wiegel T, Lohm G, Bottke D et al (2009) Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome-results of a retrospective study. Int J Radiat Oncol Biol Phys 73(4):1009-1016
35. Zelefsky MJ, Wallner KE, Ling CC et al (1999) Comparison of the 5-year outcome and morbidity of threedimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 17(2):517-522